Our Offering
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Our Company
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Archive
Media Library
Logo Guidelines
Blog
Podcast
Media Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Financial Reporting
Annual Report
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Performance
People
Planet
Community
Global Quality
Responsible Sourcing
Careers
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Our Offering
Corporate
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Our Company
Corporate
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Archive
Media Library
Logo Guidelines
Blog
Podcast
Media Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Financial Reporting
Annual Report
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Performance
People
Planet
Community
Global Quality
Responsible Sourcing
Careers
Corporate
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Corporate
Shareholders and Stock Information
Home
Investor Relations
Shareholders and Stock Information
Major shareholders according to SIX Swiss Exchange Disclosure Office
(as of 30 November 2023)
BlackRock, Inc. – 9.85%
Norges Bank (the Central Bank of Norway) – 3.04%
UBS Fund Management (Switzerland) AG – 3.01%
Find historical shareholding disclosures on the
SIX Exchange Regulation website
.
Shareholder resources
Consensus and Analysts
Overview of sell-side analysts that cover Lonza on a regular basis, and our consensus forecasts.
Learn more
Bond Investors and Credit Information
Credit Ratings: View the assessments of Lonza. Information for credit analysts, debt investors and...
Learn more
Financial Reporting
All Lonza Investor Relations reports and presentations available in the Reporting Center
Learn more
Share Buyback
Overview of Lonza’s current share buyback program.
Learn more
Investor FAQ
Overview of key investor relevant topics addressed by Lonza about its shares, general finance and...
Learn more
Previous
Next